Dr. Xin Hu is an associated professor at Department of Neurosurgery, West China Hospital of Sichuan University. Dr. Hu focuses on advancing the understanding of hemorrhagic stroke pathophysiology while developing innovative therapeutic strategies. His translational research bridges molecular mechanisms of intracerebral hemorrhage (ICH) with clinical interventions, particularly investigating secondary brain injury processes and neuroprotection approaches.
As a member of Prof. You’s team, he mentors neurosurgery residents and coordinates multicenter clinical trials through West China Hospital’s Cerebrovascular Research Center. He is one of the key members in the INTERACT3 trial, which demonstrates care bundle could benefit patients suffered with ICH. INTEACT3 brings the breakthrough for the ICH treatment and care bundle has been suggested to add into implementation during ICH management in European Stroke Consensus and Latin American Expert Consensus. He is now coordinating the execution of INTERACT5 which investigates the effect of deferoxamine and colchicine in preventing secondary brain injury in ICH. Furthermore, he is the co-principle investigator for the ENDEAVOR trial which compare the endoscopy with aspiration for treatment of basal ganglia hemorrhage.
In the basic research, Dr. Hu has great interest in the mechanism for hematoma clearance as well as the secondary brain injury after ICH. He has found that the Resolvin E1 could facilitate hematoma clearance and promotes M2 polarization of macrophages in ICH (Exp Neurol 2025) and the novel NLRP3 inhibitor, OLT1177 could attenuate brain injury in ICH (Int Immunopharmacol 2024).